Corvus Pharmaceuticals Presents New Ciforadenant Preclinical Data

 Preclinical data highlights ciforadenant’s mechanism of action and synergy with immune checkpoint inhibitors

Enrollment continues in Phase 1b/2 clinical trial evaluating ciforadenant as a potential first line therapy for metastatic RCC in combination with anti-CTLA-4 and anti-PD-1 therapies

https://www.biospace.com/article/releases/corvus-pharmaceuticals-presents-new-ciforadenant-preclinical-data-at-the-2nd-jca-aacr-precision-cancer-medicine-international-conference/